.Nature Medicine, Released online: 13 September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized stage 3b/4 DESTINY-Breast12 study, trastuzumab deruxtecan (T-DXd) treatment of clients with HER2+ enhanced breast cancer as well as energetic or dependable brain metastases revealed steady intracranial activity as well as systemic effectiveness of T-DXd.